ASLAN Pharmaceuticals Announces Expansion of Scientific Advisory Board With Appointment of Leading Global Experts in Dermatology and Immunology
14 oct. 2021 07h00 HE
|
ASLAN PHARMACEUTICALS LIMITED
MENLO PARK, Calif. and SINGAPORE, Oct. 14, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference
04 août 2021 07h00 HE
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
ASLAN Pharmaceuticals Announces Loan Facility Providing Up to $45 Million From K2 HealthVentures
13 juil. 2021 07h00 HE
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, July 13, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
22 avr. 2021 07h51 HE
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, April 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
ASLAN Pharmaceuticals Announces Pricing of Public Offering of American Depositary Shares
03 mars 2021 00h42 HE
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, March 03, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
New Research Published in Toxicology in Vitro Provides Insight Into the Hepatotoxicity of DHODH Inhibitors Suggesting ASLAN003 Has the Potential to Be Best-In-Class
26 janv. 2021 07h30 HE
|
ASLAN PHARMACEUTICALS LIMITED
— New research shows ASLAN003 to have the lowest potential for hepatotoxicity of the compounds tested despite being one of the most potent DHODH inhibitors — Data differentiates ASLAN003 from first...
ASLAN Pharmaceuticals to Develop ASLAN003 as Next Generation DHODH Inhibitor in Autoimmune Conditions
16 oct. 2020 05h25 HE
|
ASLAN PHARMACEUTICALS LIMITED
-- ASLAN believes ASLAN003 has the potential to be the most potent oral inhibitor of DHODH currently in development for autoimmune disease, more than 30 times more potent at inhibiting the DHODH...
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
18 mars 2020 05h18 HE
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, March 18, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative...
ASLAN Pharmaceuticals Announces Pricing of $12.8 Million Public Offering of American Depositary Shares
03 déc. 2019 01h00 HE
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Dec. 03, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Limited (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that it has...
ASLAN Pharmaceuticals Announces Publication of Preclinical Data on ASLAN003 in AML in Haematologica Journal
22 nov. 2019 01h30 HE
|
ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Nov. 22, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that new preclinical...